BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365 [PMID: 24966606 DOI: 10.3748/wjg.v20.i23.7356]
URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7356.htm
Number Citing Articles
1
Günaj Rakipovski, Bidda Rolin, Jane Nøhr, Ib Klewe, Klaus S. Frederiksen, Robert Augustin, Jacob Hecksher-Sørensen, Camilla Ingvorsen, Joseph Polex-Wolf, Lotte Bjerre Knudsen. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory PathwaysJACC: Basic to Translational Science 2018; 3(6): 844 doi: 10.1016/j.jacbts.2018.09.004
2
Bilal A. Omar, Bo Ahrén. Extrapancreatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibitionCardiovascular Endocrinology 2016; 5(3): 82 doi: 10.1097/XCE.0000000000000088
3
Seung Hee Choi, Jaechan Leem, In-Kyu Lee. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in MiceMediators of Inflammation 2017; 2017: 1 doi: 10.1155/2017/4139439
4
Yousaf Zafar, Ahmed Mustafa Rashid, Ahmed Kamal Siddiqi, Aayat Ellahi, Aymen Ahmed, Hassan ul Hussain, Furqan Ahmed, Ritesh G. Menezes, Tariq Jamal Siddiqi, Muhammad Talha Maniya. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology 2022; 46(7): 101970 doi: 10.1016/j.clinre.2022.101970
5
André J. Scheen. Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes MellitusClinical Pharmacokinetics 2014; 53(9): 773 doi: 10.1007/s40262-014-0157-y
6
Jose A. Gimeno-Orna, Guayente Verdes-Sanz, Laura Borau-Maorad, Julia Campos-Fernández, Beatriz Lardiés-Sánchez, Marta Monreal-Villanueva. Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonistsEndocrinología y Nutrición (English Edition) 2016; 63(4): 164 doi: 10.1016/j.endoen.2016.04.005
7
M. M. Smits, L. Tonneijck, M. H. A. Muskiet, M. H. H. Kramer, D. L. Cahen, D. H. van Raalte. Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreasDiabetes, Obesity and Metabolism 2016; 18(3): 224 doi: 10.1111/dom.12593
8
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An updateMetabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
9
Mei-Yueh Lee, Wei-Chun Chen, Wei-Hao Hsu, Szu-Chia Chen, Jin-Ching Lee. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent MechanismInternational Journal of Molecular Sciences 2019; 20(18): 4569 doi: 10.3390/ijms20184569
10
Hui Chen, Ting Cao, Bikui Zhang, Hualin Cai. The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implicationsFrontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1097284
11
Christian Baumeier, Sophie Saussenthaler, Anne Kammel, Markus Jähnert, Luisa Schlüter, Deike Hesse, Mickaël Canouil, Stephane Lobbens, Robert Caiazzo, Violeta Raverdy, François Pattou, Emma Nilsson, Jussi Pihlajamäki, Charlotte Ling, Philippe Froguel, Annette Schürmann, Robert W. Schwenk. Hepatic DPP4 DNA Methylation Associates With Fatty LiverDiabetes 2017; 66(1): 25 doi: 10.2337/db15-1716
12
Nwe Ni Than, Philip N. Newsome. A concise review of non-alcoholic fatty liver diseaseAtherosclerosis 2015; 239(1): 192 doi: 10.1016/j.atherosclerosis.2015.01.001
13
Dinali H. Fernando, Josephine M. Forbes, Peter W. Angus, Chandana B. Herath. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End ProductsInternational Journal of Molecular Sciences 2019; 20(20): 5037 doi: 10.3390/ijms20205037
14
Rehab F. Abdel-Rahman. Non-alcoholic fatty liver diseaseAsian Pacific Journal of Tropical Biomedicine 2022; 12(3): 99 doi: 10.4103/2221-1691.338919
15
Megumi Shiomi, Yoichi Tanaka, Tesshu Takada, Katsuya Otori. Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass indexJGH Open 2020; 4(5): 995 doi: 10.1002/jgh3.12384
16
Laura J Carbone, Peter W Angus, Neville D Yeomans. Incretin‐based therapies for the treatment of non‐alcoholic fatty liver disease: A systematic review and meta‐analysisJournal of Gastroenterology and Hepatology 2016; 31(1): 23 doi: 10.1111/jgh.13026
17
Eduardo García Díaz, Danila Guagnozzi, Verónica Gutiérrez, Carmen Mendoza, Cristina Maza, Yulene Larrañaga, Dolores Perdomo, Teresa Godoy, Ghalli Taleb. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot studyEndocrinología y Nutrición (English Edition) 2016; 63(5): 194 doi: 10.1016/j.endoen.2016.05.008
18
Maria Kalogirou, Emmanouil Sinakos. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?World Journal of Hepatology 2018; 10(11): 790-794 doi: 10.4254/wjh.v10.i11.790
19
Jose A. Gimeno-Orna, Guayente Verdes-Sanz, Laura Borau-Maorad, Julia Campos-Fernández, Beatriz Lardiés-Sánchez, Marta Monreal-Villanueva. Niveles de ALT y respuesta hipoglucemiante al tratamiento con agonistas del receptor de GLP-1Endocrinología y Nutrición 2016; 63(4): 164 doi: 10.1016/j.endonu.2015.11.009
20
Ides M. Colin, Henri Colin, Ines Dufour, Charles‐Edouard Gielen, Marie‐Christine Many, Jean Saey, Bernard Knoops, Anne‐Catherine Gérard. Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR)Physiological Reports 2016; 4(15) doi: 10.14814/phy2.12886
21
Eduardo García Díaz, Danila Guagnozzi, Verónica Gutiérrez, Carmen Mendoza, Cristina Maza, Yulene Larrañaga, Dolores Perdomo, Teresa Godoy, Ghalli Taleb. Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: estudio observacional pilotoEndocrinología y Nutrición 2016; 63(5): 194 doi: 10.1016/j.endonu.2016.01.006
22
Takayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizu. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model MiceInternational Journal of Molecular Sciences 2015; 16(12): 29207 doi: 10.3390/ijms161226156
23
Eunüs S. Ali, Jin Hua, Claire H. Wilson, George A. Tallis, Fiona H. Zhou, Grigori Y. Rychkov, Greg J. Barritt. The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca 2+ signalling in steatotic hepatocytesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research 2016; 1863(9): 2135 doi: 10.1016/j.bbamcr.2016.05.006
24
Noriyuki Kaji, Yoshiichi Takagi, Satomi Matsuda, Anna Takahashi, Sakurako Fujio, Fumitoshi Asai. Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat dietAnimal Models and Experimental Medicine 2020; 3(1): 62 doi: 10.1002/ame2.12106
25
Ines Bilic Curcic, Maja Cigrovski Berkovic, Lucija Kuna, Hrvoje Roguljic, Robert Smolic, Silvija Canecki Varzic, Lucija Virovic Jukic, Martina Smolic. Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?Journal of Clinical and Translational Hepatology 2019; 7(3): 1 doi: 10.14218/JCTH.2019.00029
26
Tian Shen, Bilin Xu, Tao Lei, Lin Chen, Cuiping Zhang, Zhenhua Ni. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathwayExperimental and Therapeutic Medicine 2018;  doi: 10.3892/etm.2018.6554
27
Zuo-Di Fu, Xiao-Ling Cai, Wen-Jia Yang, Ming-Ming Zhao, Ran Li, Yu-Feng Li. Novel glucose-lowering drugs for non-alcoholic fatty liver diseaseWorld Journal of Diabetes 2021; 12(1): 84-97 doi: 10.4239/wjd.v12.i1.84
28
Sara Salehi Hammerstad, Shira Frankel Grock, Hanna J. Lee, Alia Hasham, Nina Sundaram, Yaron Tomer. Diabetes and Hepatitis C: A Two-Way AssociationFrontiers in Endocrinology 2015; 6 doi: 10.3389/fendo.2015.00134